Mike Powell

Mike Powell

Chairman | Executive Partner at Omega Funds

Read More

Mike has more than 25 years of pharmaceutical development experience and has focused on clinical-stage product companies, particularly in the oncology and neurology areas. He is currently Executive Partner at Omega Funds and was Managing General Partner at Sofinnova Investments from 1997-2021. Prior to becoming a venture capitalist, Mike worked on 20 clinical products and authored almost 100 papers and books, including an 1,000–page treatise on vaccine design. Mike was the initial investor in a number of companies that went public, including: Actelion (SWX: ATLN), InterMune (Nasdaq: ITMN), Orexigen Therapeutics (Nasdaq: OREX), Seattle Genetics (Nasdaq: SGEN), Threshold Pharmaceuticals (Nasdaq: THLD) and Trius Therapeutics (Nasdaq: TSRX), as well as several private companies, including Intellikine (acquired by Millennium/Takeda), Labrys Biologics (acquired by Teva) and Pionyr Therapeutics (partnered with Gilead). Mike is currently Board Chair of Galera Therapeutics (Nasdaq: GRTX), and on the Board of Trustees of Washington University in St. Louis. He is past Board President of AVAC (AIDS Vaccine Advocacy Coalition) in NYC, a former Advisor to the Bill and Melinda Gates Foundation, a former Strategic Advisor to One World Health and a Founding Venture Advisory Board member of the IAVI (International AIDS Vaccine Initiative) Innovation Fund. He is an Adjunct Professor in Pharmaceutical Chemistry at the University of Kansas and served on the advisory board of the Institute for the Advancement of Medical Innovation at the University of Kansas. Mike had senior level operation roles at Genentech, Cytel, and Syntex Research and was the first scientist from the biotechnology industry to be elected a Fellow of the American Association of Pharmaceutical Scientists. He received his PhD in Physical Chemistry from the University of Toronto, and a postdoc at the University of California, where he was a faculty member before moving into biotech.

Keith Flaherty

Keith Flaherty, MD

Director

Read More

Dr. Flaherty is a Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, Director of Clinical Research, Massachusetts General Hospital Cancer Center and Editor-in-Chief of Clinical Cancer Research. He co-founded and served on the Board of Directors of Loxo Oncology, Inc. until its acquisition by Eli Lilly and Company and he currently serves on the Board of Directors of Clovis Oncology, Inc. (NASDAQ: CLVS). Dr. Flaherty has a Bachelor of Science from Yale University and medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.

Oren K. Isacoff, MD

Oren K. Isacoff, MD

Director

Read More

Dr. Isacoff is a Principal at Longitude Capital. Prior to joining Longitude Capital in 2015, Dr. Isacoff was a Senior Associate on the Healthcare Team of TPG Special Situations Partners. Dr. Isacoff completed his internship at Massachusetts General Hospital and maintains an active medical license. Dr. Isacoff is a board observer at Inozyme, KaNDy Therapeutics and Velicept Therapeutics, and has been actively involved with Longitude Capital’s investments in Cydan Development, Poseida Therapeutics and Tricida (TCDA). He previously served as a board observer at Zavante Therapeutics (acquired by Nabriva).

Dr. Isacoff holds an MD and an MBE from the Perelman School of Medicine, an MBA from the Wharton School, and a BA in Political Science and a BS in Economics from the University of Pennsylvania.

Peter Colabuono

Peter Colabuono

Director

Read More

Peter is Principal at Decheng Capital, which he joined in October 2016. In addition this expertise in finance, investment, transaction, operational and drug development, he brings a passion to find a cure for cancer and bring life-saving drugs to patients. Prior to joining Decheng, Peter held positions in business and corporate development, sales and marketing, and company startups. As Associate at Frazier Healthcare Ventures, he led the investment and company formation for Silvergate Pharmaceuticals, a pediatric rare disease company that to date has launched four internally developed and proprietary products, and served as Vice President of Business Development & Managed Care at the company. At Frazier, he was involved in and served as board observer for Calistoga Pharmaceuticals, VentiRx, Alnara Pharma, and Oceana Therapeutics, as well as several of the firm’s public investments. Prior to Frazier, he served in the Morgan Stanley and Cowen Healthcare Investment Banking groups. Mr. Colabuono holds a B.A. in Molecular Biology and Biochemistry from Dartmouth College, is an inventor and author on issued patents and journal articles, and is active with the Head & Neck Cancer Alliance.

Alan Fuhrman headshot

Alan Fuhrman

Interim CEO & President

Read More

Mr. Fuhrman is an experienced financial operations leader with a focus on guiding the growth of innovative pharmaceutical and biotechnology companies. Alan is a member of the Board of Directors for SpringWorks Therapeutics and Esperion Therapeutics. Alan also served on the Board of Directors and as Chair of the Audit Committee for Loxo Oncology until its sale to Eli Lilly in the first quarter of 2019. He previously served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020. Prior to joining Amplyx, he served as CFO of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company that merged with Synlogic in August 2017. Alan previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. Earlier in his career, Alan practiced as a certified public accountant with Coopers & Lybrand. Alan received a B.S. in both Business Administration and Agricultural Economics from Montana State University.

Nilesh Kumar, PhD

Nilesh Kumar, PhD

Director

Read More

Nilesh Kumar is a Partner at Novo Ventures and is responsible for investments in Morphic Therapeutics (NASDAQ: MORF), Milestone Pharmaceuticals (NASDAQ: MIST), Tarveda Therapeutics, Anokion, Cirius Therapeutics, Rgenix Therapeutics, and Disc Medicine. Prior to joining Novo, Nilesh was Senior Director at Merck Ventures where he invested in early stage life science companies. He led the initial investments and served on the Boards of Padlock Therapeutics (acquired by BMS), f-star, RaNA Therapeutics (NASDAQ: TBIO), and Auxogyn (NASDAQ: PGNY).

Nilesh received his PhD from the Department of Chemistry and Chemical Biology at Harvard University and holds an MBA from Harvard University. He completed his undergraduate degree in Natural Sciences at the University of Cambridge, UK.